GSK: Result Summaries: Compounds > fondaparinux

Home > Result Summaries: Compounds > fondaparinux

Result Summaries: fondaparinux

Result Summaries for fondaparinux
GSK Study ID	Phase	Title	Summary (Download)
63102	Phase 1	A single, rising dose study of the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous Org31540/SR90107A in healthy male and female elderly volunteers (0 citation(s))
63103	Phase 1	A repeated rising-dose, placebo-controlled study of the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous Org31540/SR90107A administered for 7 consecutive days to healthy male and female elderly volunteers (4 citation(s))
63105	Phase 1	A study to evaluate safety, tolerability and pharmacokinetics of 2, 4, 6, 12, 16,18, and 20 mg of the pentasaccharide Org31540/SR90107A, administered as a single intravenous bolus injection to healthy elderly subjects (2 citation(s))
63106	Phase 1	A four-period cross-over study to assess the absolute bioavailability, safety and tolerability of the pentasaccharide Org31540/SR90107A, after single dose subcutaneous administration of 2, 4 and 8 mg compared with 4 mg intravenous administration to healthy elderly subjects (1 citation(s))
63107	Phase 1	Study to Assess the Safety/Tolerability and the Pharmacokinetics/Pharmacodynamics of Org31540/SR90107A Administered As A Single Intravenous Bolus Injection to Healthy Volunteers and Patients with Impaired Renal Function (2 citation(s))
63108	Phase 1	An interaction study with subcutaneously administered Org31540/SR90107A and oral warfarin in healthy male volunteers (Protocol 63108) (3 citation(s))
63113	Phase 2	A randomized, assessor-blind, dose reducing, phase II study to assess the safety and efficacy of 10, 8, 6 and 4 mg Org31540/SR90107A and standard treatment with intravenous fragmin in patients with chronic intermittent haemodialysis (0 citation(s))
63118	Phase 3	European Pentasaccharide Hip Elective Surgery Study (EPHESUS): A multicenter, randomized, double-blind comparison of once daily subcutaneous Org31540/SR90107A with enoxaparin for the prevention of deep vein thrombosis or symptomatic pulmonary embolism in patients undergoing elective hip replacem ... (8 citation(s))
63119	Phase 2	A double blind, randomized, controlled, dose ranging study of Org31540/SR90107A in patients with unstable angina pectoris: PENTUA (1 citation(s))
63123	Phase 3	A multicentre, randomized, open-label study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus adjusted dose intravenous (i.v.) unfractionated heparin (UFH) in the initial treatment of acute symptomatic pulmonary embolism (PE) (MATISSE-PE) (18 citation(s))
63128	Phase 1	A phase I interaction trial to investigate the pharmacodynamics and pharmacokinetics of 10 mg subcutaneous Org31540/SR90107A and intravenous recombinant Factor VIIa, in healthy male volunteers. (1 citation(s))
63132	Phase 1	A phase I trial to evaluate and compare the safety, pharmacokinetics and pharmacodynamics of a single dose of 7.5mg subcutaneous Org31540/SR90107A in subjects with moderate hepatic impairment and subjects with normal liver function (0 citation(s))
95001	Phase 2	A multicenter, concurrent control, randomized, open-label, assessor-blind, dose-ranging study of Org 31540/SR90107A in the prophylaxis of deep vein thrombosis in subjects undergoing total knee replacement surgery (PENTATAK). (1 citation(s))
DRI2440 – Rembrandt	Phase 2	A Multicentre, Randomized, Double-Blind, Dose Ranging Study of Org31540/SR90107A in the Initial Treatment of Symptomatic Proximal Deep Vein Thrombosis (DVT) (1 citation(s))

Filter list by: